ArticleCancer research communications2026
Cell-Free DNA-Derived Immune Cell Ratios Uncover Cancer-Associated Systemic Changes.
Article in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Genome-wide coverage patterns of plasma cell-free DNA (cfDNA) fragments reflect nucleosome positioning in the cells of origin, enabling noninvasive inference of cell type contributions and transcriptional activity. Whereas the majority of cfDNA originates from hematopoietic cells, the diagnostic and biological relevance of this fraction remains underexplored. In this study, we performed cfDNA-based deconvolution of blood cell types by integrating transcription start site (TSS) coverage profiles from plasma whole-genome sequencing with single-cell transcriptomic reference data. By correlating cfDNA TSS coverage with gene expression across 457 blood cell types, we ranked their relative contributions to the cfDNA pool. We analyzed 788 pretreatment and longitudinal plasma samples from patients with localized colorectal cancer, muscle-invasive bladder cancer (MIBC), as well as 30 samples from healthy controls. In healthy individuals, cfDNA TSS coverage profiles reflected blood gene expression, and the inferred cell type contributions recapitulated the known hematopoietic composition. In patients with cancer, we observed a significant increase in cfDNA contributions from lymphocytes, including T cells and plasma cells, and decreased contributions from monocytes and granulocytes. These immune-derived signatures distinguished patients with colorectal cancer (AUC = 0.793) and MIBC (AUC = 0.745) from healthy controls. Longitudinal analysis of immune cell type contributions revealed treatment-associated changes in the relative abundance of classic monocytes and plasma cells, although these temporal dynamics were not predictive of relapse or outcome. Together, these findings suggest that cfDNA-derived immune signatures may capture aspects of systemic immune remodeling in cancer, potentially providing a complementary noninvasive biomarker in liquid biopsies beyond tumor-derived signals. SIGNIFICANCE: There is limited understanding of how plasma cfDNA reflects systemic immune changes in cancer. We show that cfDNA coverage profiles reflect blood cell gene expression and can be used to infer blood cell ranks that recapitulate known cell compositions. These cfDNA-derived ranks reveal cancer-associated immune alterations that distinguish patients with cancer from healthy controls. Our findings highlight cfDNA as a minimally invasive biomarker of systemic immune remodeling in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.